pirlindole free base

Pirlindole is a reversible inhibitor of monoamine oxidase A (RIMA). It is structurally and pharmacologically related to metralindole.

Pirlindole作为一种可逆的单胺氧化酶A (RIMA) 抑制剂，主要在俄罗斯作为抗抑郁化合物开发并使用。它在结构和药理学上与metralindole相似。Pirlindole已在一些欧洲和非欧洲国家批准用于治疗抑郁症。其口服绝对生物利用度为20%至30%，主要因为显著的首过效应。对于大鼠而言，其口服Tmax在2.5至6小时之间变化；对于狗，该值在0.8至2小时之间。

Pirlindole, 一种可逆性单胺氧化酶A (RIMA) 抑制剂，在俄罗斯被开发并用作抗抑郁药。该化合物与metralindole 在结构和药理学上有关联。Pirlindole 已在一些欧洲和非欧洲国家批准用于治疗抑郁症。由于广泛的首过效应，Pirlindole 的绝对生物利用度介于20%至30%之间。口服时，其在大鼠中的Tmax变化范围为2.5至6小时，而在狗中为0.8至2小时。

monoamine oxidase type A inhibitor

Pirlindole-d4 is intended for use as an internal standard for the quantification of pirlindole by GC- or LC-MS. Pirlindole is a selective and reversible monoamine oxidase A (MAO-A) inhibitor. It is selective for MAO-A over MAO-B. In rats, it reverses the depressive-like effects induced by chronic mild stress (CMS), increases proliferation of hippocampal neural progenitor cells, and reverses dendritic atrophy in granule neurons. Pirlindole is also an inhibitor of enterovirus-D68 and coxsackievirus B3 (CV-B3), inhibiting the genome replication phase of CV-B3 infection with an EC50 value of 7.7 µM independent of MAO-A activity.